Recursion Pharmaceuticals (RXRX) Income from Continuing Operations (2020 - 2026)
Recursion Pharmaceuticals (RXRX) posted Income from Continuing Operations of 117504000.0 for Q1 2026, down 8.68% on a QoQ basis from 108122000.0 in Q4 2025, and up 41.97% year-over-year from 82767010.29 in Q1 2025.
Recursion Pharmaceuticals (RXRX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 117504000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 41.97% year-over-year to 117504000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 559776000.0 (up 2.61% YoY) and the FY2025 annual result came in at 644759000.0, down 39.06% from the prior year.
- Income from Continuing Operations was 117504000.0 for Q1 2026 at Recursion Pharmaceuticals, down from 108122000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 55995000.0 in Q1 2022 and bottomed at 202487000.0 in Q1 2025.
- A 5-year average of 106077411.76 and a median of 93017000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations sank 121.6% — and 2026, when it soared 41.97%.
- Recursion Pharmaceuticals' Income from Continuing Operations stood at 64540000.0 in 2022, then plunged by 44.09% to 92996000.0 in 2023, then sank by 92.38% to 178906000.0 in 2024, then soared by 39.56% to 108122000.0 in 2025, then declined by 8.68% to 117504000.0 in 2026.
- Business Quant data shows RXRX's Income from Continuing Operations at 117504000.0 in Q1 2026, 108122000.0 in Q4 2025, and 162253000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Recursion Pharmaceuticals | 1.57 Bn | 912.05 Mn | -6.02 Mn | -117.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -117.50 Mn |
| Dec 31, 2025 | -108.12 Mn |
| Sep 30, 2025 | -162.25 Mn |
| Jun 30, 2025 | -171.90 Mn |
| Mar 31, 2025 | -202.49 Mn |
| Dec 31, 2024 | -178.91 Mn |
| Sep 30, 2024 | -95.84 Mn |
| Jun 30, 2024 | -97.54 Mn |
| Mar 31, 2024 | -91.37 Mn |
| Dec 31, 2023 | -93.00 Mn |
| Sep 30, 2023 | -93.02 Mn |
| Jun 30, 2023 | -76.73 Mn |
| Mar 31, 2023 | -65.33 Mn |
| Dec 31, 2022 | -64.54 Mn |
| Sep 30, 2022 | -62.59 Mn |
| Jun 30, 2022 | -66.21 Mn |
| Mar 31, 2022 | -56.00 Mn |
| Dec 31, 2021 | -64.98 Mn |
| Sep 30, 2021 | -46.62 Mn |
| Jun 30, 2021 | -43.43 Mn |